The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).
Periodical measures of the clinical features with UPDRS will be done at the beginning, each three months until two years. Each group will be compare to evaluate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
VIUSID/ALZER, 3 per day, oral, one year
Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
"Salvador Allende Hospital"
Havana, La Habana, Cuba
Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment)
Time frame: one year
Hoehn-Yarh will be done at the beginning, every three months until one year (end of the treatment)
Time frame: one year
Dosage levodopa will be done at the beginning, every three months until one year (end of the treatment)
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.